Company Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer
•February 16, 2026
0
Why It Matters
The AI‑CRISPR blend showcases a faster, more scalable route to combat emerging infections, reshaping investment and regulatory landscapes in biotech.
Key Takeaways
- •AI and CRISPR combined for rapid disease diagnostics
- •ASF proof‑of‑concept cut pig viremia significantly
- •Pathogen mapping speeds target identification
- •FDA engagement early reduces approval timelines
- •Turnaround expertise drives biotech resilience
Pulse Analysis
Seek Labs exemplifies how the convergence of artificial intelligence and gene‑editing tools can revitalize the infectious‑disease sector. By leveraging AI to sift through massive genomic datasets, the company accelerates pathogen identification and designs CRISPR‑based therapeutics in weeks rather than months. This approach not only shortens discovery timelines but also lowers R&D costs, positioning Seek Labs as a nimble competitor in a market traditionally dominated by large, slower‑moving firms.
The African Swine Fever (ASF) proof‑of‑concept serves as a tangible benchmark for the platform’s potential. In controlled trials, the CRISPR‑engineered therapy reduced viral load in pigs, demonstrating both efficacy and a clear path to commercial livestock applications. Parallel AI‑driven pathogen mapping enables rapid generation of target sequences, allowing the team to pivot quickly when new strains emerge. Such agility is critical as zoonotic threats continue to rise, offering a template for tackling human viral diseases with similar speed.
Regulatory strategy is another cornerstone of Seek Labs’ roadmap. Early dialogues with the FDA and international agencies help shape trial designs that meet safety standards while expediting review cycles. This proactive stance reduces uncertainty for investors and accelerates market entry. As the biotech ecosystem increasingly values speed, precision, and cost‑effectiveness, Seek Labs’ model could set a new standard for how AI and CRISPR are deployed to address global health challenges.
Original Description
On this week's episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases. Jared explains the technology convergence that was needed to build Seek Labs' AI diagnostic and CRISPR-based therapeutics platform, an African Swine Fever proof-of-concept study that reduced viremia in pigs, mapping pathogens for rapid target design, and engaging with the FDA and global regulatory agencies.
Access this and hundreds of episodes of the Business of Biotech videocast at lifescienceleader.com
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:
0
Comments
Want to join the conversation?
Loading comments...